AbbVie posted $15.42 billion in Q2 revenue, topping estimates, with strong immunology and neuroscience growth, while ...

AbbVie released positive topline data from its phase 3 UP-AA trial demonstrating safety and efficacy for upadacitinib for ...

AbbVie has reported encouraging topline outcomes from the first of two replicate trials of the Phase III UP-AA programme, assessing Rinvoq (upadacitinib), at both 15mg and 30mg doses in adult and ...

Sun Pharmaceutical Industries reported a 20% decline in net profit for Q1 FY26, but adjusted profits excluding exceptions ...

As Women with Alopecia Awareness Month comes to a close, WRBL spoke to a local woman impacted by the autoimmune condition.

Forget the trip to Turkey. Top hair-restoration doctors are touting less invasive treatments that, coupled with the latest ...

The FDA granted fast track designation for rezpegaldesleukin for treating adults and children aged 12 years and older, ...

The FDA has granted a “Fast Track” designation to rezpegaldesleukin (REZPEG) as a treatment for severe-to-very severe ...

Those who get their hair back after an episode of alopecia probably didn’t have moderate to severe hair loss. Learn about ...

Nektar Therapeutics ( NASDAQ: NKTR) has announced that the FDA has awarded Fast Track designation to its experimental drug rezpegaldesleukin, a treatment for severe-to-very severe alopecia areata.

Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of severe-to-very severe ...

Rezpegaldesleukin targets the interleukin-2 receptor complex in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells.